We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Virtusa, RH, M/I Homes, Mr. Cooper Group and Medifast
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 15, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Virtusa Corporation , RH (RH - Free Report) , M/I Homes, Inc. (MHO - Free Report) , Mr. Cooper Group Inc. (COOP - Free Report) and Medifast, Inc. (MED - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top-Ranked Stocks that Surged More than 10% Last Week
Wall Street's astonishing bull run for more than five months suffered a major setback in early September. The rally hit the highest level on Sep 2 since it recorded the recent trough on Mar 23 but thereafter a sharp downtrend made investors nervous. The holiday-shortened last week was the worst in several months.
Historically, September is known as the worst-performing month in Wall Street. Market participants started panicking that the coronavirus-defying rally would terminate this month. However, a closer look at the market last week revealed that not all stocks suffered due to the pulldown.
Technology Sector Leads Market Mayhem
The technology sector pulled down the overall market after being the predominant driver of the impressive showing over the last five months. It was technology that had helped Wall Street to exit a coronavirus-induced short bear market and form a new bull market.
However, in the due course of the market's V-shaped recovery from its recent trough on Mar 23, technology stocks got overvalued, as stated by many financial experts.
Within the S&P 500 Index, the technology sector plunged 11.1% from Sep 3 to Sep 11. The tech-heavy Nasdaq Composite plummeted 10% and entered into correction territory. However, a massive selloff of technology stocks had a ripple effect, resulting in overall market turmoil.
Wall Street in Turmoil
Last week was highly disappointing for Wall Street. The Dow was down 1.7% last week, marking its second-straight negative week. The S&P 500 lost 2.5%, reflecting its second-straight weekly loss for the first time since May 1, and its worst week since Jun 26.
The Nasdaq Composite tumbled 4.1%, marking its worst weekly performance since Mar 20. Notably, out of 11 broad sectors of the S&P 500 Index, only the materials sector managed to finish in positive territory with a slender gain of 0.8% for the week.
Large scale selling of technology stocks owing to overvaluation concerns, delay in new fiscal stimulus deal, heightening geopolitical tensions between the United States and China, and halt in clinical trials of a leading drug for the potential treatment of COVID-19 were the primary reasons for last week's market turmoil.
Month to date, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — are down 2.7%, 4.6% and 7.8%, respectively. Notably, all three indexes recorded gains in the last five months in a row. However, despite extreme volatility so far this month, a few stocks have popped.
Our Top Picks
We have narrowed down our search to five stocks that have rallied more than 10% in the last week. All these stocks have strong growth potential and witnessed robust earnings estimate revisions within the last 7 to 60 days. Each of our picks carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Virtusa provides digital engineering and information technology (IT) outsourcing services primarily in North America, Europe and Asia. Although the company's expected earnings growth rate for the current year (ending March 2021) is negative, it has an expected earnings growth rate of 21.6% for next year. The Zacks Consensus Estimate for current-year earnings has improved 24.7% over the last 60 days. The stock price soared 27.4% last week.
RH operates as a retailer in the home furnishings. It offers products in various categories, including furniture, lighting, textiles, bathware, décor, outdoor and garden, tableware, and child and teen furnishings. The company has an expected earnings growth rate of 32.9% for the current year (ending January 2021). The Zacks Consensus Estimate for the current year has improved 31.4% over the last 7 days. The stock price jumped 20.4% last week.
M/I Homes operates as a builder of single-family homes in the United States. It operates through four segments: Midwest Homebuilding, Southern Homebuilding, Mid-Atlantic Homebuilding and Financial Services. The company has an expected earnings growth rate of 36.7% for the current year. The Zacks Consensus Estimate for the current year has improved 91.2% over the past 60 days. The stock price rallied 12% last week.
Mr. Cooper Group provides quality servicing, origination and transaction-based services principally to single-family residences in the United States. Its brand consists of Mr. Cooper and Xome. The company has expected earnings growth of more than 100% for the current year. The Zacks Consensus Estimate for the current year has improved 85.3% over the last 60 days. The stock price appreciated 11.3% last week.
Medifast manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company has an expected earnings growth rate of 37.1% for the current year. The Zacks Consensus Estimate for current year earnings has improved 18.4% over the past 60 days. The stock price advanced 10.8% last week.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Virtusa, RH, M/I Homes, Mr. Cooper Group and Medifast
For Immediate Release
Chicago, IL – September 15, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Virtusa Corporation , RH (RH - Free Report) , M/I Homes, Inc. (MHO - Free Report) , Mr. Cooper Group Inc. (COOP - Free Report) and Medifast, Inc. (MED - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top-Ranked Stocks that Surged More than 10% Last Week
Wall Street's astonishing bull run for more than five months suffered a major setback in early September. The rally hit the highest level on Sep 2 since it recorded the recent trough on Mar 23 but thereafter a sharp downtrend made investors nervous. The holiday-shortened last week was the worst in several months.
Historically, September is known as the worst-performing month in Wall Street. Market participants started panicking that the coronavirus-defying rally would terminate this month. However, a closer look at the market last week revealed that not all stocks suffered due to the pulldown.
Technology Sector Leads Market Mayhem
The technology sector pulled down the overall market after being the predominant driver of the impressive showing over the last five months. It was technology that had helped Wall Street to exit a coronavirus-induced short bear market and form a new bull market.
However, in the due course of the market's V-shaped recovery from its recent trough on Mar 23, technology stocks got overvalued, as stated by many financial experts.
Within the S&P 500 Index, the technology sector plunged 11.1% from Sep 3 to Sep 11. The tech-heavy Nasdaq Composite plummeted 10% and entered into correction territory. However, a massive selloff of technology stocks had a ripple effect, resulting in overall market turmoil.
Wall Street in Turmoil
Last week was highly disappointing for Wall Street. The Dow was down 1.7% last week, marking its second-straight negative week. The S&P 500 lost 2.5%, reflecting its second-straight weekly loss for the first time since May 1, and its worst week since Jun 26.
The Nasdaq Composite tumbled 4.1%, marking its worst weekly performance since Mar 20. Notably, out of 11 broad sectors of the S&P 500 Index, only the materials sector managed to finish in positive territory with a slender gain of 0.8% for the week.
Large scale selling of technology stocks owing to overvaluation concerns, delay in new fiscal stimulus deal, heightening geopolitical tensions between the United States and China, and halt in clinical trials of a leading drug for the potential treatment of COVID-19 were the primary reasons for last week's market turmoil.
Month to date, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — are down 2.7%, 4.6% and 7.8%, respectively. Notably, all three indexes recorded gains in the last five months in a row. However, despite extreme volatility so far this month, a few stocks have popped.
Our Top Picks
We have narrowed down our search to five stocks that have rallied more than 10% in the last week. All these stocks have strong growth potential and witnessed robust earnings estimate revisions within the last 7 to 60 days. Each of our picks carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Virtusa provides digital engineering and information technology (IT) outsourcing services primarily in North America, Europe and Asia. Although the company's expected earnings growth rate for the current year (ending March 2021) is negative, it has an expected earnings growth rate of 21.6% for next year. The Zacks Consensus Estimate for current-year earnings has improved 24.7% over the last 60 days. The stock price soared 27.4% last week.
RH operates as a retailer in the home furnishings. It offers products in various categories, including furniture, lighting, textiles, bathware, décor, outdoor and garden, tableware, and child and teen furnishings. The company has an expected earnings growth rate of 32.9% for the current year (ending January 2021). The Zacks Consensus Estimate for the current year has improved 31.4% over the last 7 days. The stock price jumped 20.4% last week.
M/I Homes operates as a builder of single-family homes in the United States. It operates through four segments: Midwest Homebuilding, Southern Homebuilding, Mid-Atlantic Homebuilding and Financial Services. The company has an expected earnings growth rate of 36.7% for the current year. The Zacks Consensus Estimate for the current year has improved 91.2% over the past 60 days. The stock price rallied 12% last week.
Mr. Cooper Group provides quality servicing, origination and transaction-based services principally to single-family residences in the United States. Its brand consists of Mr. Cooper and Xome. The company has expected earnings growth of more than 100% for the current year. The Zacks Consensus Estimate for the current year has improved 85.3% over the last 60 days. The stock price appreciated 11.3% last week.
Medifast manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company has an expected earnings growth rate of 37.1% for the current year. The Zacks Consensus Estimate for current year earnings has improved 18.4% over the past 60 days. The stock price advanced 10.8% last week.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.